The recent retirement of Aratana Therapeutics Inc.’s COO, coupled with a key stakeholder significantly reducing its holdings, suggests that the once-imminent sale of the Leawood-based animal health company may be growing less likely.
COO Brent Standridge left the company Dec. 31, according to a Jan 4. filing with the Securities and Exchange Commission.
“Standridge retired to spend more time with his family,” an Aratana spokeswoman said. "He joined Aratana as a consultant about 2.5 years ago…
